Get the Stockscreener App
3.31
0.30%
0.01
After Hours:
3.31
Acumen Pharmaceuticals Inc stock is traded at $3.31, with a volume of 390.93K.
It is up +0.30% in the last 24 hours and up +28.79% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$3.30
Open:
$3.2
24h Volume:
390.93K
Relative Volume:
0.69
Market Cap:
$200.50M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-2.9554
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
+19.93%
1M Performance:
+28.79%
6M Performance:
+138.13%
1Y Performance:
+187.83%
1-Day Range:
$3.01
$3.41
1-Week Range:
$2.68
$3.41
52-Week Range:
$0.8551
$3.41
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
617-344-4190
Address
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
3.31 | 199.89M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen Pharmaceuticals to showcase advances in Alzheimer's treatment at international conference on Alzheimer's and Parkinson's diseases 2026 - marketscreener.com
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 - Bitget
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 - The Manila Times
Acumen Pharmaceuticals To Showcase Advances In Alzheimer's Treatment At International Conference On Alzheimer’S And Parkinson’S Diseases 2026 - TradingView
New Alzheimer’s treatment data explores better delivery to the brain - Stock Titan
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Acumen Pharmaceuticals (NASDAQ: ABOS) insider sells 9,406 shares - Stock Titan
ABOS Should I Buy - Intellectia AI
Profit Review: Can Acumen Pharmaceuticals Inc reach resistance levels soonTrend Reversal & Daily Chart Pattern Signals - baoquankhu1.vn
ABOS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded at Wall Street Zen - MarketBeat
Does Acumen Pharmaceuticals Inc. stock have upside surprise potentialJuly 2025 Spike Watch & Safe Capital Preservation Plans - mfd.ru
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Market Trends: How is BlackSky Technology Inc Equity Warrant managing supply chain issuesJuly 2025 Recap & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Growth in Short Interest - Defense World
Will Acumen Pharmaceuticals Inc. stock reach Wall Street targetsWeekly Trend Report & Daily Risk Controlled Trade Plans - mfd.ru
Decliners Report: Is Acumen Pharmaceuticals Inc a cyclical or defensive stockJuly 2025 Summary & Long-Term Growth Plans - baoquankhu1.vn
ABOS PE Ratio & Valuation, Is ABOS Overvalued - Intellectia AI
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Increase in Short Interest - MarketBeat
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results - The Malaysian Reserve
Can Acumen Pharmaceuticals Inc. stock sustain institutional interest2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - mfd.ru
Doseology Sciences Launches New Energy Product Line - Intellectia AI
Acumen Pharmaceuticals celebrates team contributions - Traders Union
Brokerages Set Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Price Target at $6.80 - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS) - The Globe and Mail
Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
While Institutions Invested in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Benefited From Last Week's 46% Gain, Private Equity Firms Stood to Gain the Most - 富途牛牛
Acumen Pharma CLO sells $53k in shares after option exercise - Investing.com Canada
Healthcare Stocks Surge in After-Hours Trading - intellectia.ai
Wall Street Analysts Adjust Ratings - intellectia.ai
Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments - Yahoo Finance
2026 Catalysts: Psychiatry, epilepsy and neurodegeneration - BioCentury
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $7.00 at BTIG Research - MarketBeat
Are Insider Tax-Related Sales Misaligned With Acumen Pharmaceuticals’ (ABOS) Alzheimer’s Trial Progress Narrative? - Sahm
Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
ABOS: BTIG Raises Price Target to $7.00, Maintains Buy Rating | - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Acumen Pharmaceuticals’ Share Volatility: Insight Into Recent Developments - StocksToTrade
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Does Sabirnetug’s Phase 2 Extension and Insider Stock Sales Alter the Bull Case for ABOS? - Yahoo Finance
Acumen Pharmaceuticals CEO sells shares worth $21993 - Investing.com Nigeria
Acumen Pharmaceuticals CLO sells shares worth $16,720 By Investing.com - Investing.com South Africa
Acumen Pharma CFO Zuga sells shares worth $7.6k By Investing.com - Investing.com Canada
Acumen Pharmaceuticals CEO sells shares worth $21993 By Investing.com - Investing.com South Africa
Daniel Joseph Oconnell Sells 9,346 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock - MarketBeat
Acumen Pharmaceuticals CLO sells shares worth $16,720 - Investing.com
Acumen Pharma CMO Siemers sells $5.8k in ABOS stock By Investing.com - Investing.com UK
"Study Within A Study" Reveals Best Recruitment Strategies For Alzheimer's Trials - Clinical Leader
January 2026's Rising Stars: Top Penny Stocks To Watch - simplywall.st
VIX Spike: How does Acumen Pharmaceuticals Inc perform in inflationary periods2025 Technical Overview & Smart Swing Trading Techniques - baoquankhu1.vn
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.71%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):